Efficacy Biomarkers of DAOIB for Dementia

Condition(s) studied

Investigational drug(s) / intervention(s)

DAOIB: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.

Study summary

This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.

Eligibility

Primary outcome measure(s)

• Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24 — week 0, 8, 16, 24
  Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)

Trial sites (2)

More Chang Gung Memorial Hospital trials in China

Other trials for the same condition